A study protocol for a multicenter randomized pilot trial of a dyadic, tailored, web-based, psychosocial, and physical activity self-management program (TEMPO) for men with prostate cancer and their caregivers.

Cancer rehabilitation Cancer survivorship Caregivers Dyadic intervention Prostate cancer Self-management

Journal

Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536

Informations de publication

Date de publication:
20 Mar 2021
Historique:
received: 15 10 2020
accepted: 08 02 2021
entrez: 21 3 2021
pubmed: 22 3 2021
medline: 22 3 2021
Statut: epublish

Résumé

Prostate cancer predisposes patients and caregivers to a wide range of complex physical and psychosocial challenges, and interventions must incorporate a wide range of self-management strategies to help patients and their caregivers effectively cope with cancer challenges. To palliate this need, our team recently developed and evaluated the initial acceptability of a dyadic, Tailored, wEb-based, psychosocial, and physical activity self-Management PrOgram (TEMPO). TEMPO is a 10-week, interactive, web-based intervention consisting of five modules designed to help dyads manage their physical and psychosocial needs. It aims to teach dyads new self-management strategies and encourages them to increase their physical activity (PA) levels, mainly through walking and strength-based exercises. Initial acceptability evaluation of TEMPO revealed high user satisfaction, in addition to having a number of potential benefits for participants. After integrating suggested changes to TEMPO, the proposed pilot study aims to further test the acceptability and feasibility of TEMPO. This study is a multicenter, stratified, parallel, two-group, pilot randomized control trial (RCT), where patient-caregiver dyads are randomized (stratified by anxiety level) to receive (a) TEMPO or (b) usual care. Participants (n goal = 40) are recruited across Canada at participating cancer centers and through self-referral (e.g., online recruitment). Patient inclusion criteria are (a) having received prostate cancer treatment within the past 2 years or scheduled to receive treatment, (b) identified a primary caregiver willing to participate in the study, and (c) has access to the Internet. Eligible caregivers are those identified by the patient as his primary source of support. Dyads complete a baseline questionnaire (T1) and another one 3 months later (T2) assessing various aspects of physical and emotional functioning (e.g., the Medical Outcomes Study (MOS) 12-item Short Form Health Survey (SF-12), the Hospital Anxiety and Depression Scale (HADS), and the Perceived Stress Scale (PSS)), self-management behaviors (e.g., the Health Education Impact Questionnaire (heiQ)), physical activity (the International Physical Activity Questionnaires (IPAQ) and the Multidimensional Self-efficacy for Exercise Scale (MSES)), and dyadic coping (the Dyadic Coping Inventory (DCI)). Dyads that used TEMPO are also asked to participate in a semi-structured exit interview exploring their overall experience with the program. This feasibility analysis will begin to develop the knowledge base on TEMPO's value for men with prostate cancer and their caregivers to inform a larger trial. NCT04304196.

Sections du résumé

BACKGROUND BACKGROUND
Prostate cancer predisposes patients and caregivers to a wide range of complex physical and psychosocial challenges, and interventions must incorporate a wide range of self-management strategies to help patients and their caregivers effectively cope with cancer challenges. To palliate this need, our team recently developed and evaluated the initial acceptability of a dyadic, Tailored, wEb-based, psychosocial, and physical activity self-Management PrOgram (TEMPO). TEMPO is a 10-week, interactive, web-based intervention consisting of five modules designed to help dyads manage their physical and psychosocial needs. It aims to teach dyads new self-management strategies and encourages them to increase their physical activity (PA) levels, mainly through walking and strength-based exercises. Initial acceptability evaluation of TEMPO revealed high user satisfaction, in addition to having a number of potential benefits for participants. After integrating suggested changes to TEMPO, the proposed pilot study aims to further test the acceptability and feasibility of TEMPO.
METHODS METHODS
This study is a multicenter, stratified, parallel, two-group, pilot randomized control trial (RCT), where patient-caregiver dyads are randomized (stratified by anxiety level) to receive (a) TEMPO or (b) usual care. Participants (n goal = 40) are recruited across Canada at participating cancer centers and through self-referral (e.g., online recruitment). Patient inclusion criteria are (a) having received prostate cancer treatment within the past 2 years or scheduled to receive treatment, (b) identified a primary caregiver willing to participate in the study, and (c) has access to the Internet. Eligible caregivers are those identified by the patient as his primary source of support. Dyads complete a baseline questionnaire (T1) and another one 3 months later (T2) assessing various aspects of physical and emotional functioning (e.g., the Medical Outcomes Study (MOS) 12-item Short Form Health Survey (SF-12), the Hospital Anxiety and Depression Scale (HADS), and the Perceived Stress Scale (PSS)), self-management behaviors (e.g., the Health Education Impact Questionnaire (heiQ)), physical activity (the International Physical Activity Questionnaires (IPAQ) and the Multidimensional Self-efficacy for Exercise Scale (MSES)), and dyadic coping (the Dyadic Coping Inventory (DCI)). Dyads that used TEMPO are also asked to participate in a semi-structured exit interview exploring their overall experience with the program.
DISCUSSION CONCLUSIONS
This feasibility analysis will begin to develop the knowledge base on TEMPO's value for men with prostate cancer and their caregivers to inform a larger trial.
TRIAL REGISTRATION BACKGROUND
NCT04304196.

Identifiants

pubmed: 33743804
doi: 10.1186/s40814-021-00791-6
pii: 10.1186/s40814-021-00791-6
pmc: PMC7980105
doi:

Banques de données

ClinicalTrials.gov
['NCT04304196']

Types de publication

Journal Article

Langues

eng

Pagination

78

Subventions

Organisme : Prostate Cancer Canada
ID : TAG2015-03

Références

Value Health. 2009 Sep;12(6):958-66
pubmed: 19490549
Med Sci Sports Exerc. 2010 Jul;42(7):1409-26
pubmed: 20559064
Ann Behav Med. 2016 Dec;50(6):907-919
pubmed: 27439530
J Cancer Surviv. 2021 Apr;15(2):281-310
pubmed: 32930924
J Oncol Pract. 2013 Jul;9(4):197-202
pubmed: 23942921
J Clin Med. 2020 Oct 13;9(10):
pubmed: 33066225
J Clin Oncol. 2006 Jul 20;24(21):3465-73
pubmed: 16849763
J Psychosoc Oncol. 2005;23(2-3):23-43
pubmed: 16492650
Trials. 2010 Nov 29;11:115
pubmed: 21114863
Ann Behav Med. 2012 Oct;44(2):225-35
pubmed: 22740365
Cancer. 2014 Oct 15;120(20):3228-36
pubmed: 24988944
Res Q Exerc Sport. 2008 Jun;79(2):222-34
pubmed: 18664046
J Clin Epidemiol. 2004 Jun;57(6):571-9
pubmed: 15246125
Health Qual Life Outcomes. 2015 May 24;13:64
pubmed: 26306793
CA Cancer J Clin. 2010 Sep-Oct;60(5):317-39
pubmed: 20709946
BMJ. 2008 Sep 29;337:a1655
pubmed: 18824488
Patient Educ Couns. 2007 May;66(2):192-201
pubmed: 17320338
Int J Occup Med Environ Health. 2012 Jun;25(2):178-84
pubmed: 22528542
Clin Psychol Rev. 2013 Jun;33(4):609-22
pubmed: 23603521
Nurs Open. 2020 Jun 28;7(5):1299-1312
pubmed: 32802350
Patient Educ Couns. 2017 Jun;100(6):1213-1221
pubmed: 28089132
Eur J Cancer Care (Engl). 2016 Sep;25(5):806-21
pubmed: 26507369
J Psychosom Res. 2012 Mar;72(3):173-4
pubmed: 22325694
Oncol Nurs Forum. 2002 Nov-Dec;29(10):1411-9
pubmed: 12432412
Cancer. 2007 Dec 15;110(12):2809-18
pubmed: 17999405
J Affect Disord. 2013 May;147(1-3):171-9
pubmed: 23218249
Nurs Res. 2007 Jan-Feb;56(1):44-53
pubmed: 17179873
Psychol Assess. 2013 Jun;25(2):379-90
pubmed: 23356678
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S383-412
pubmed: 22588759
Asian Nurs Res (Korean Soc Nurs Sci). 2012 Dec;6(4):121-7
pubmed: 25031113
Support Care Cancer. 2010 Oct;18(10):1241-62
pubmed: 20596731
Psychooncology. 2013 Jun;22(6):1229-35
pubmed: 22715124
Support Care Cancer. 2013 Dec;21(12):3451-60
pubmed: 23955024
Psychooncology. 2017 Jul;26(7):873-913
pubmed: 28691760
Aust N Z J Public Health. 2001 Oct;25(5):464-9
pubmed: 11688629
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Psychooncology. 2013 Dec;22(12):2639-47
pubmed: 23840033
Int J Nurs Stud. 2013 May;50(5):587-92
pubmed: 23159157
J Psychosom Res. 2002 Feb;52(2):69-77
pubmed: 11832252
Prog Community Health Partnersh. 2011 Spring;5(1):27-34
pubmed: 21441666
Ann Behav Med. 2018 Jul 13;52(8):645-661
pubmed: 30010704
J Consult Clin Psychol. 2004 Dec;72(6):1122-35
pubmed: 15612858
J Consult Clin Psychol. 2003 Dec;71(6):1036-48
pubmed: 14622079
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Front Psychol. 2017 May 23;8:834
pubmed: 28596746
BMJ. 2010 Mar 23;340:c869
pubmed: 20332511
Spine (Phila Pa 1976). 2017 Dec 15;42(24):1908-1916
pubmed: 28658040
Psychooncology. 2013 Mar;22(3):555-63
pubmed: 22290823
Med J Aust. 2010 Sep 6;193(S5):S68-73
pubmed: 21542450
Cancer Nurs. 2014 Sep-Oct;37(5):321-30
pubmed: 24945270
Ann Behav Med. 2008 Oct;36(2):117-28
pubmed: 18830672
J Fam Psychol. 2007 Sep;21(3):380-8
pubmed: 17874923
Health Soc Care Community. 2019 Sep;27(5):e622-e636
pubmed: 31293013
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Am J Occup Ther. 2013 Mar-Apr;67(2):154-61
pubmed: 23433269
BMC Public Health. 2013 Jul 16;13:658
pubmed: 23855504
Clin J Oncol Nurs. 2007 Oct;11(5):723-7
pubmed: 17962180
Integr Cancer Ther. 2015 Sep;14(5):446-51
pubmed: 25917816
J Clin Epidemiol. 1998 Nov;51(11):1171-8
pubmed: 9817135
BMJ Open. 2013 Jul 24;3(7):
pubmed: 23883890
Psychooncology. 2011 Sep;20(9):919-25
pubmed: 20669337
BMJ Support Palliat Care. 2012 Sep;2(3):224-30
pubmed: 24654195
Clin Epidemiol. 2018 Jan 18;10:153-157
pubmed: 29403314
Health Qual Life Outcomes. 2008 Jul 02;6:46
pubmed: 18597689
Psychooncology. 2015 Dec;24(12):1605-17
pubmed: 26059915
SAGE Open Med. 2018 Sep 21;6:2050312118801250
pubmed: 30319778
Oncol Nurs Forum. 2014 May;41(3):257-64
pubmed: 24769590
Pilot Feasibility Stud. 2016 May 20;2:25
pubmed: 27965844
Support Care Cancer. 2016 Feb;24(2):711-722
pubmed: 26184499
Psychooncology. 2002 Mar-Apr;11(2):93-102
pubmed: 11921325
Cancer Nurs. 2009 Nov-Dec;32(6):482-92
pubmed: 19816159
J Phys Act Health. 2017 Jul;14(7):578-595
pubmed: 28290737
Prostate Cancer. 2020 Jan 29;2020:4393175
pubmed: 32231798

Auteurs

Sylvie D Lambert (SD)

Ingram School of Nursing, McGill University, Montreal, Quebec, Canada. sylvie.lambert@mcgill.ca.
St. Mary's Research Centre, Montreal, Quebec, Canada. sylvie.lambert@mcgill.ca.

Lindsay R Duncan (LR)

Department of Kinesiology and Physical Education, McGill University, Montreal, Quebec, Canada.

Janet Ellis (J)

Department of Psychiatry, University of Toronto, Toronto, Canada.
Psychosocial Care in Trauma, Sunnybrook Health Sciences Centre, Toronto, Canada.

John Wellesley Robinson (JW)

Department of Psychology, University of Calgary, Calgary, Canada.
Department of Oncology, University of Calgary, Calgary, Canada.

Carly Sears (C)

University of Calgary, Calgary, Canada.

Nicole Culos-Reed (N)

Health and Exercise Psychology, Faculty of Kinesiology, University of Calgary, Calgary, Canada.
Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada.
Psychosocial Resources, Tom Baker Cancer Centre, Cancer Care, Alberta Health Services, Edmonton, Canada.

Andrew Matthew (A)

Faculty of Medicine, Department of Surgery, University of Toronto, Toronto, Canada.
Department of Psychiatry, University of Toronto, Toronto, Canada.
Department of Surgery, Princess Margaret Cancer Centre, Toronto, Canada.

Manon De Raad (M)

St. Mary's Research Centre, Montreal, Quebec, Canada.

Jamie Lynn Schaffler (JL)

St. Mary's Research Centre, Montreal, Quebec, Canada.

Daniel Santa Mina (DS)

Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, Canada.
Toronto General Hospital, Toronto, Canada.

Paramita Saha-Chaudhuri (P)

Department of Mathematics and Statistics, University of Vermont, Burlington, VT, USA.

Helen McTaggart-Cowan (H)

Canadian Centre for Applied Research in Cancer Control, Toronto, Canada.
Cancer Control Research, BC Cancer, Vancouver, Canada.

Stuart Peacock (S)

Canadian Centre for Applied Research in Cancer Control, Toronto, Canada.
Cancer Control Research, BC Cancer, Vancouver, Canada.
Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.

Classifications MeSH